成人呼吸衰竭及相关适应证的体外生命支持:综述
本综述回顾了成人急性呼吸衰竭体外生命支持(ECLS)的循证历程:1970–1990年代临床试验未显示获益,2009年随机试验及甲型H1N1流感大流行期间的使用重新激发兴趣,2018年针对极重度急性呼吸窘迫综合征的随机试验报告死亡率从46%降至35%但差异无统计学意义,贝叶斯事后分析及后续荟萃分析提示ECLS对极重度急性呼吸窘迫综合征可能有益。随着证据增加,适应证扩展至肺移植桥接及伴右心衰竭的肺血管疾病。ECLS已成为临床实践中可接受的器官支持形式。
要点
- 2018年随机试验:极重度急性呼吸窘迫综合征成人ECLS组死亡率35% vs 对照组46%,差异未达统计学显著。
- 对该试验的贝叶斯事后分析及后续荟萃分析提示ECLS对极重度急性呼吸窘迫综合征可能有益。
- ECLS适应证已扩展至肺移植桥接及伴右心衰竭的肺血管疾病管理。
- 技术改进使ECLS更安全,但早期(1970–1990年代)临床试验未证实获益。
适用人群与场景
- 成人急性呼吸衰竭患者,尤其是急性呼吸窘迫综合征患者
- 极重度急性呼吸窘迫综合征成人患者(2018年随机试验人群)
- 作为肺移植桥接的患者
- 伴右心衰竭的肺血管疾病患者
研究设计与关键结果
- 综述汇总:1970–1990年代成人急性呼吸衰竭ECLS临床试验未显示获益,导致该干预使用减少并局限于少数中心。
- 2009年发表了一项急性呼吸衰竭ECLS随机临床试验,同期甲型H1N1流感大流行中重症急性呼吸窘迫综合征患者使用了ECLS。
- 2018年一项针对极重度急性呼吸窘迫综合征患者的随机临床试验显示死亡率从46%降至35%,但差异未达统计学显著。
- 对该试验的贝叶斯事后分析及后续荟萃分析提示ECLS对极重度急性呼吸窘迫综合征患者可能有益。
证据类型、等级与局限
- 证据类型:综述(Review)。
- 2018年随机试验主要结果差异未达统计学显著,但贝叶斯事后分析和荟萃分析提示可能获益。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于极重度急性呼吸窘迫综合征成人患者,ECLS可作为可接受的器官支持形式,但2018年随机试验的死亡率差异未达统计学显著,贝叶斯事后分析及荟萃分析提示可能获益。
- ECLS适应证已扩展至作为肺移植桥接及伴右心衰竭的肺血管疾病管理。
指南或共识出处
- JAMA综述:Extracorporeal Life Support for Adults With Respiratory Failure and Related Indications: A Review.
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: The substantial growth over the last decade in the use of extracorporeal life support for adults with acute respiratory failure reveals an enthusiasm for the technology not always consistent with the evidence. However, recent high-quality data, primarily in patients with acute respiratory distress syndrome, have made extracorporeal life support more widely accepted in clinical practice.
OBSERVATIONS: Clinical trials of extracorporeal life support for acute respiratory failure in adults in the 1970s and 1990s failed to demonstrate benefit, reducing use of the intervention for decades and relegating it to a small number of centers. Nonetheless, technological improvements in extracorporeal support made it safer to use. Interest in extracorporeal life support increased with the confluence of 2 events in 2009: (1) the publication of a randomized clinical trial of extracorporeal life support for acute respiratory failure and (2) the use of extracorporeal life support in patients with severe acute respiratory distress syndrome during the influenza A(H1N1) pandemic. In 2018, a randomized clinical trial in patients with very severe acute respiratory distress syndrome demonstrated a seemingly large decrease in mortality from 46% to 35%, but this difference was not statistically significant. However, a Bayesian post hoc analysis of this trial and a subsequent meta-analysis together suggested that extracorporeal life support was beneficial for patients with very severe acute respiratory distress syndrome. As the evidence supporting the use of extracorporeal life support increases, its indications are expanding to being a bridge to lung transplantation and the management of patients with pulmonary vascular disease who have right-sided heart failure. Extracorporeal life support is now an acceptable form of organ support in clinical practice.
CONCLUSIONS AND RELEVANCE: The role of extracorporeal life support in the management of adults with acute respiratory failure is being redefined by advances in technology and increasing evidence of its effectiveness. Future developments in the field will result from technological advances, an increased understanding of the physiology and biology of extracorporeal support, and increased knowledge of how it might benefit the treatment of a variety of clinical conditions.
参考来源
- Brodie D, Slutsky AS, Combes A, et al. Extracorporeal Life Support for Adults With Respiratory Failure and Related Indications: A Review. JAMA. 2019. PMID: 31408142. doi:10.1001/jama.2019.9302
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。